U.S. Life Sciences Stock News

If you are wondering whether Avantor's current share price reflects its true worth, you are not alone. This article is built to help you size up that valuation clearly. The stock recently closed at US$9.11, with returns of 0.7% over 7 days, a 22.8% decline over 30 days, a 20.5% decline year to date, and a 48.1% decline over 1 year that some investors may see as a reset in expectations. Over the past 3 and 5 years, Avantor's share price has recorded declines of 62.6% and 68.3%, which has put...

USA Rare Earth, ticker NasdaqGM:USAR, has been involved in advising on a landmark $1.6b federal equity transaction. The deal supports government backed investment in the U.S. critical minerals sector, with a focus on non dilutive funding. The company is working alongside Clark Street Associates as part of this federal initiative. For you as an investor, this news places USA Rare Earth in the middle of a high profile federal push to support domestic rare earths. The stock currently trades at...

Earlier in February 2026, West Pharmaceutical Services’ board declared a regular quarterly dividend of US$0.22 per share and approved a new share repurchase program of up to US$1.00 billion with no expiration date, following its fourth-quarter and full-year 2025 results and updated 2026 guidance. Together, the fresh US$1.00 billion buyback authorization, ongoing dividend payments, and management’s 2026 outlook highlight the company’s current focus on returning capital to shareholders while...

Aurora Innovation, Inc. has already reported its fourth-quarter and full-year 2025 results, posting US$1 million in quarterly sales and a full-year net loss of US$816 million, while analysts have recently highlighted its progress in autonomous trucking, including more than 4.5 million autonomous miles and expansion to 10 routes. Despite the still-small revenue base and large losses, Aurora’s completion of 250,000 fully driverless miles with zero collisions and plans to operate over 200...

If you are trying to figure out whether Williams-Sonoma is still reasonably priced after a strong multi year run, starting with a clear look at valuation can help ground your view before you act. The stock last closed at US$208.97, with returns of 2.2% over 30 days, 11.2% year to date and 8.1% over 1 year, while the 3 year and 5 year returns are both very large. Recent headlines have focused on Williams-Sonoma's positioning in home furnishings and its brand strength with higher income...

Earlier this month, The Walt Disney Company reported fiscal 2026 first-quarter results showing weaker entertainment and sports operating income amid higher content and marketing costs, alongside cautious guidance pointing to ongoing earnings pressure and limited near-term margin recovery. These developments have intensified investor focus on whether Disney’s heavy investment in streaming and premium sports rights can be balanced with profitability as its traditional TV business faces...

If you are wondering whether W.W. Grainger's recent share price puts it at a premium or a bargain, this article will walk through what that current price could mean for value focused investors. The stock last closed at US$1,126.68, with returns of 6.5% over 30 days, 12.2% year to date, 13.3% over 1 year and 73.1% over 3 years, while the past 7 days show a 0.5% decline. Recent attention on W.W. Grainger has centered on its role as a large industrial supplies distributor in the US capital...

XPEL, Inc. has reported past fourth-quarter 2025 results showing revenue of US$122.27 million and net income of US$13.41 million, alongside basic earnings per share from continuing operations of US$0.49. The company has also issued new guidance for first-quarter 2026 revenue of about US$112 million to US$114 million, giving investors a clearer view of near-term expectations. Now we’ll explore how this revenue guidance range shapes XPEL’s existing investment narrative and expectations for its...

XPO (XPO) is in focus after rolling out AI tools that analyze dockworker photos to improve freight safety and reduce damage claims, while a Supreme Court tariff ruling could reshape cost dynamics for many of its shipping customers. See our latest analysis for XPO. XPO’s recent AI rollout and the tariff ruling arrive as momentum is already strong, with a 30 day share price return of 38.88% and a year to date share price return of 47.37%, alongside a 1 year total shareholder return of 67.51%...

If you are wondering whether Genuine Parts shares are now attractively priced or still expensive, this article walks through what the current market price might be implying about the company's value. The stock recently closed at US$118.82, with a 5.5% decline over 7 days, a 13.7% decline over 30 days and a 4.2% decline year to date. The 1 year return is a 0.4% decline and the 3 year return is a 26.8% decline, compared to a 24.8% gain over 5 years. Recent news coverage has focused on Genuine...

Recent performance snapshot Elanco Animal Health (ELAN) has caught investor attention after a strong 1 year total return of 146.5%, alongside positive moves over the past week, month and past 3 months. See our latest analysis for Elanco Animal Health. The current share price of US$26.38 sits against a 1 year total shareholder return of 146.5%, with recent 1 day and 30 day share price returns of 6.6% and 8.1%. This suggests that momentum remains strong rather than fading. If strong recent...

GXO’s Hunkemoller partnership and tech rollout come into focus GXO Logistics (GXO) is in the spotlight after launching a multi-year partnership with Hunkemoller in Almere, where advanced automation supports a pan-European distribution network and expands GXO’s Flevoland logistics campus. See our latest analysis for GXO Logistics. These automation wins come as GXO’s 30 day share price return of 9.96% and 90 day share price return of 25.01% outpace its 16.26% year to date share price return,...

Investors may be wondering whether Alcoa at around US$61.41 a share is offering good value today, or if the easy gains are already behind it. The stock has returned 6.9% over the last 7 days, is roughly flat over 30 days with a 1.3% decline, and is showing gains of 8.6% year to date and 81.0% over the last year. This naturally raises questions about how the market is now pricing its risks and opportunities. Recent coverage of Alcoa has focused on its role as a major aluminum producer, with...

CarMax has appointed former InterContinental Hotels Group CEO Keith Barr as its new Chief Executive Officer, President and Board member, effective March 16, 2026, with interim leader David McCreight returning to his role as independent director. Barr’s background in large-scale digital transformation, customer experience and brand-led growth in hospitality introduces a fresh cross-industry leadership approach to CarMax’s used-vehicle retail model. Next, we’ll examine how Barr’s digital and...

John Wiley & Sons (WLY) has drawn fresh attention after announcing a major expansion of its Advanced Portfolio, with eight new life, health, and social sciences journals planned by the end of 2026. See our latest analysis for John Wiley & Sons. At a share price of $29.35, John Wiley & Sons has experienced a 30 day share price return of a 5.6% decline and a 90 day share price return of an 18.49% decline, while its 1 year total shareholder return of a 23.77% decline suggests longer term...

If you are wondering whether VICI Properties is offering good value at its current price, this article will walk through what the numbers actually say about the stock. Recently, VICI Properties closed at US$30.28, with returns of 1.4% over 7 days, 6.1% over 30 days, 7.6% year to date, 6.4% over 3 years, 38.0% over 5 years and a 1.7% decline over the last year. Investors have been watching VICI as it continues to feature in discussions around large scale experiential real estate and its role...

In recent weeks, Fabrinet reported quarterly results and guidance that exceeded expectations, highlighting strong demand for its AI and data center–related optical manufacturing services and reinforcing its role as a key outsourced partner in these fast-growing hardware segments. The company also announced acquisitions and a pivot toward higher-margin business lines, while analyst upgrades and institutional interest highlighted Fabrinet’s improved positioning within the technology supply...

Recent performance context for Visa (V) Visa (V) has recently drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past week, month, past 3 months, year to date, and past year. At a last close of US$307.22, Visa sits against a backdrop of multi year total returns, solid reported revenue of US$41.39b and net income of US$20.59b, as well as a value score of 3. See our latest analysis for Visa. Visa’s recent share price returns...

In February 2026, XP Inc. filed a US$215.58 million shelf registration for 9,393,589 Class A shares after reporting fourth-quarter 2025 revenue of BRL 4,938 million and net income of BRL 1,282 million, both higher than a year earlier. The combination of year-on-year growth in revenue, earnings per share and client assets, alongside completion of a recent share buyback, underlines XP’s emphasis on scaling its platform while actively managing its capital structure. We’ll now examine how XP’s...

AGNC Investment Corp. recently declared a cash dividend of US$0.12 per common share for February 2026, payable on March 10 to shareholders of record as of February 27, while its 2025 10-K highlighted an Agency RMBS portfolio of US$94.80 billion and solid returns. This combination of continued monthly dividends and sizable, actively managed mortgage holdings underscores how AGNC is leaning on income stability and portfolio scale to support investor confidence. Next, we will examine how AGNC’s...

If you are wondering whether Somnigroup International at around US$88.62 is still good value after a strong run, you are not alone. This article focuses on what the current price could imply about the stock. The share price has returned 1.0% over the last 7 days, 37.2% over the past year and 112.9% over 3 years. The 30 day return of 4.4% and year to date return of 0.1% show that recent moves have been more muted. Recent news coverage around Somnigroup International has highlighted investor...

Why DexCom Stock Is On Investors’ Radar DexCom (DXCM) has drawn fresh attention after recent trading left the shares near US$73, even as the stock shows mixed return patterns across the past week, month, past 3 months and year. See our latest analysis for DexCom. At around US$73, DexCom’s recent 7 day share price return of 3.78% and 90 day share price return of 16.89% contrasts with a 1 year total shareholder return decline of 17.24%. This suggests short term momentum while longer term...

Wondering if Allstate at around US$209.82 is still a sensible entry point, or if the easy gains are behind it? You are not alone in asking whether the current price lines up with the company’s underlying value. The stock has had a mixed short term patch, with a 1.2% decline over the last 7 days, an 8.4% gain over 30 days, a 2.9% return year to date, and a 12.3% return over the past year. The 3 year and 5 year returns stand at 73.6% and 114.8% respectively. Recent headlines around Allstate...

NouvoCure (NVCR) is back in focus after British Columbia agreed to fund its Tumor Treating Fields therapy for newly diagnosed glioblastoma, marking the first provincial reimbursement for this treatment in Canada. See our latest analysis for NovoCure. The British Columbia reimbursement news comes on top of February’s FDA approval of Optune Pax for locally advanced pancreatic cancer, and together these updates appear to have supported a 6.92% 1 day share price return and 5.48% 7 day share price...